First, in AIS patients, the numbers of circulating stem cells (CD133+) and early EPCs (CD133+/VEGFR2+) upon admission were similar to those in control individuals without AIS; however, the risk factors were similar. This evidence concerns the gene PROM1 and androgen insensitivity syndrome.